{"id":"yl201","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, YL201 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased blood glucose levels. This mechanism is primarily used to treat type 2 diabetes.","oneSentence":"YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07487896","phase":"PHASE3","title":"A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-04-30","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":440},{"nctId":"NCT06057922","phase":"PHASE1, PHASE2","title":"A Study YL201 in Patients With Selected Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2023-09-22","conditions":"Advanced Solid Tumor","enrollment":990},{"nctId":"NCT07407933","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03","conditions":"Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma","enrollment":118},{"nctId":"NCT06898957","phase":"PHASE1","title":"Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-05-16","conditions":"Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07258979","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-11-05","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":202},{"nctId":"NCT07208773","phase":"PHASE1, PHASE2","title":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-10-29","conditions":"Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":260},{"nctId":"NCT05434234","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2022-05-25","conditions":"Advanced Solid Tumor","enrollment":312},{"nctId":"NCT06241846","phase":"PHASE2","title":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-02-22","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":100},{"nctId":"NCT06394414","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-04-17","conditions":"Advanced Solid Tumors","enrollment":162},{"nctId":"NCT06612151","phase":"PHASE3","title":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-17","conditions":"Small Cell Lung Cancer","enrollment":438},{"nctId":"NCT06629597","phase":"PHASE3","title":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-31","conditions":"Nasopharyngeal Carcinoma","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Serplulimab","Platinum"],"phase":"phase_3","status":"active","brandName":"YL201","genericName":"YL201","companyName":"MediLink Therapeutics (Suzhou) Co., Ltd.","companyId":"medilink-therapeutics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}